Zhengzhou Handu Pharmaceutical Co. Ltd.

Main purpose: This study used Olopatadine Hydrochloride Tablets certified by Zhengzhou Handu Pharmaceutical Group Co., Ltd. as the test preparation and Olopatadine Hydrochloride Tablets (trade name: Allelock) certified by Kyowa Kirin Co., Ltd. as the reference preparation to conduct a human bioequivalence test under fasting/fed conditions. Secondary purpose: To evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects.

Main purpose: Using the indobufen tablets (specification: 0.2g) certified by Zhengzhou Handu Pharmaceutical Group Co., Ltd. as the test preparation, and the indobufen tablets (trade name: Ibustrin, specification: 0.2g) certified by Pfizer Italia S.r.l. as the reference preparation, a human bioequivalence test was conducted under fasting/postprandial conditions to evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects. Secondary purpose: Observe the safety of the test preparation and the reference preparation in healthy subjects.

Primary objective: To observe the pharmacokinetic characteristics of the test preparation Moxifloxacin Hydrochloride Tablets (Specification: 0.4g (calculated as C21H24FN3O4); Manufacturer: Zhengzhou Handu Pharmaceutical Group Co., Ltd.) and the reference preparation Moxifloxacin Hydrochloride Tablets (Trade name: Avelox®; Specification: 0.4g (calculated as C21H24FN3O4); Licensee: Bayer Vital GmbH) in Chinese healthy subjects after a single oral administration in the fasting/fed state, and to evaluate the bioequivalence of the two preparations in the fasting/fed state. Secondary objective: To observe the safety of the test preparation Moxifloxacin Hydrochloride Tablets and the reference preparation Moxifloxacin Hydrochloride Tablets (Avelox®) in Chinese healthy subjects.